PAVmed Inc.PAVM

PAVmed Inc. filed its first-quarter 2026 10-Q on 14 May 2026, and the numbers tell a tale of a company making noise outside the ledger while the ledger itself stays quiet. Revenue from contract with customer, excluding assessed tax, for the quarter was $22,000. Net income attributable to the parent was -$60,000, and operating loss came in at -$8.0 million. Cash and cash equivalents stood at $6.5 million, while net cash used in operating activities was -$2.6 million. The company’s stockholders’ equity was $39.5 million against liabilities of $20.4 million. Diluted earnings per share were -$4.42 on 1.6 million diluted shares outstanding. (source: PAVM 10-Q (2026-05-14), https://www.sec.gov/Archives/edgar/data/1624326/000143774926017121/pavm20260331_10q.htm)

Lucid Diagnostics, PAVmed’s diagnostic arm, reports a more colourful story. In Q1 2026 it processed 3,177 EsoGuard® tests and booked $1.3 million in revenue. The product is a DNA test that swabs the oesophagus to spot early signs of Barrett’s oesophagus before cancer can take hold. The company’s pro-forma cash position is $45 million, giving it a runway that stretches into 2027 and beyond the next key reimbursement milestone. Yet PAVmed’s consolidated revenue for the quarter remains at $22,000, a figure that looks oddly small when set against the $1.3 million headline from the subsidiary. (source: Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results, https://ir.pavmed.com/2026-05-14-Lucid-Diagnostics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results)

PAVmed’s management touts a “relaunched medical device portfolio” under Joseph Virgilio’s leadership, including the PortIO intraosseous vascular access device and an endoscopic esophageal imaging technology licensed from Duke University. The company also says it is evaluating additional acquisition opportunities. On the capital side, PAVmed’s cash burn is visible: R&D expense was $1.4 million for the quarter, and capitalised software and equipment purchases were a mere $22,000. The company’s 8-K filings in May 2026 disclose insider and institutional shareholdings via updated Schedule 13G forms, but none of the documents disclose a clear path to GAAP profitability. (source: PAVM 8-K (2026-05-15), https://www.sec.gov/Archives/edgar/data/1624326/000149315226029944/form8-k.htm)

If you want a chart route, the SEC’s company facts endpoint quietly updates daily with XBRL exhibits for PAVmed. The data lives at the SEC’s API, not on TradingView, and the filings themselves are the only public source for revenue, cash, and equity metrics. The SEC index page for PAVmed is the canonical rail, not the cheerleading slide deck. (source: PAVmed SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1624326)

The tension in the file is simple: the subsidiary is selling tests and building cash, while the parent’s consolidated numbers remain thin. EsoGuard’s Medicare reimbursement outlook is the obvious swing factor. A positive draft local coverage determination would trigger the Series D warrant call at $0.001 per share, a clause that looks generous until you remember the warrants sit with insiders and institutions. Until GAAP profitability shows up in the 10-Q, the ledger still carries a red ink tone. (source: PAVmed 10-Q (2026-05-14), https://www.sec.gov/Archives/edgar/data/1624326/000143774926017121/pavm20260331_10q.htm)

PAVmed’s board and management are running a company that looks like two businesses in one: a diagnostics spin-out making revenue and cash, and a parent company that still looks like a development-stage medtech portfolio with a burn rate. The runway is long, the science is promising, but the consolidated numbers have not caught up to the pitch. What would change the file next? A GAAP profit in the 10-Q, or a Medicare draft local coverage determination that turns the warrant call clause from curiosity into concrete value. Until then, the gap between the polished platform story and the filed numbers remains the story. (source: PAVM 8-K (2026-06-24), https://www.sec.gov/Archives/edgar/data/1624326/000149315226029944/form8-k.htm)